8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Mar 24, 2026·SEC
Material company update
Mar 2, 2026·SEC
Sanara MedTech Inc.(SMTI)Earnings, Financials & Key Ratios
SMTI•NASDAQ
Price updated Jun 19, 2026
AboutSanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.Show more
- Revenue$103M+19.0%
- EBITDA$12M+758.8%
- Net Income-$38M-288.7%
- EPS (Diluted)-4.36-282.5%
- Gross Margin90.13%-0.5%
- EBITDA Margin11.45%+653.8%
- Operating Margin8.87%+214.5%
- Net Margin-36.43%-226.7%
- ROE-167.53%-623.7%
SMTI Key Insights
Sanara MedTech Inc. (SMTI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 45.9%
- ✓Efficient asset utilization: 1.4x turnover
✗Weaknesses
- ✗High debt to equity ratio of 8.1x
- ✗Profits declining 53.9% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 32.0x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SMTI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SMTI Price & Volume
Sanara MedTech Inc. (SMTI) stock price & volume — 10-year historical chart
Loading chart...
SMTI Growth Metrics
Sanara MedTech Inc. (SMTI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years40.78%
5 Years45.92%
3 Years31.03%
TTM17.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-193.85%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-190.97%
Return on Capital
10 Years-27.9%
5 Years-15.12%
3 Years-1.17%
Last Year14.39%
SMTI Recent Earnings
Sanara MedTech Inc. (SMTI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.04+200.0%
$0.04
Rev
$28M+3.7%
$27M
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$0.04-63.6%
$0.11
Rev
$28M+0.5%
$27M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.09+137.5%
$0.24
Rev
$26M-3.2%
$27M
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.23+30.3%
$0.33
Rev
$26M-2.9%
$27M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.04vs $0.04+200.0% | $28Mvs $27M+3.7% |
| Q2 2026 | Mar 24, 2026 | $0.04vs $0.11-63.6% | $28Mvs $27M+0.5% |
| Q4 2025 | Nov 12, 2025 | $0.09vs $0.24+137.5% | $26Mvs $27M-3.2% |
| Q3 2025 | Aug 13, 2025 | $0.23vs $0.33+30.3% | $26Mvs $27M-2.9% |
Based on last 12 quarters of dataView full earnings history →
SMTI Peer Comparison
Sanara MedTech Inc. (SMTI) competitors in Wound care and infection prevention — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 XTNT | 61.8M | 0.44 | 14.69 | 14.21% | 1.5% | 3.68% | 0.56 | |
 MDXG | 545.24M | 3.67 | 11.47 | 19.99% | 7.88% | 12.86% | 0.09 | |
 KROS | 340.78M | 10.65 | 4.63 | 67.75% | -256.6% | -17.04% | 0.06 | |
 BLCO | 5.3B | 14.87 | -14.58 | 6.47% | -4.21% | -3.37% | 0.82 | |
 CWST | 5.45B | 86.98 | 724.83 | 17.95% | 0.38% | 0.46% | 0.79 | |
 HROW | 1.6B | 42.87 | -306.21 | 36.41% | -5.57% | -33.92% | 4.84 | |
 SRDX | 614.51M | 42.98 | -52.41 | -4.91% | -14.59% | -15.59% | 0.28 |
Compare SMTI vs Peers
Sanara MedTech Inc. (SMTI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SMTI Income Statement
Sanara MedTech Inc. (SMTI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 6.3M | 5.84M | 11.77M | 15.59M | 24.14M | 45.84M | 64.99M | 86.67M | 103.12M | 107.51M |
Revenue Growth % | 14.47% | -7.41% | 101.56% | 32.47% | 54.9% | 89.87% | 41.77% | 33.36% | 18.97% | 17.41% |
Cost of Goods Sold | 806.04K | 507.42K | 1.21M | 1.62M | 2.31M | 6.36M | 7.85M | 8.14M | 10.18M | 9.48M |
COGS % of Revenue | 12.78% | 8.69% | 10.28% | 10.37% | 9.57% | 13.88% | 12.08% | 9.39% | 9.87% | - |
Gross Profit | 5.5M▲ 0% | 5.33M▼ 3.1% | 10.56M▲ 98.1% | 13.97M▲ 32.3% | 21.83M▲ 56.3% | 39.48M▲ 80.8% | 57.14M▲ 44.7% | 78.53M▲ 37.4% | 92.94M▲ 18.3% | 98.03M▲ 0% |
Gross Margin % | 87.22% | 91.31% | 89.72% | 89.63% | 90.43% | 86.12% | 87.92% | 90.61% | 90.13% | 91.19% |
Gross Profit Growth % | 20.47% | -3.06% | 98.06% | 32.33% | 56.28% | 80.84% | 44.72% | 37.45% | 18.34% | - |
Operating Expenses | 5.36M | 5.82M | 13.3M | 19M | 29.21M | 52M | 61.35M | 85.25M | 83.79M | 89.56M |
OpEx % of Revenue | 84.95% | 99.69% | 113.01% | 121.93% | 120.98% | 113.43% | 94.4% | 98.36% | 81.26% | - |
Selling, General & Admin | 5.28M | 5.74M | 13.07M | 18.67M | 28.05M | 45.98M | 56.99M | 76.56M | 78.72M | 61.81M |
SG&A % of Revenue | 83.67% | 98.25% | 111.05% | 119.8% | 116.19% | 100.29% | 87.7% | 88.33% | 76.34% | - |
Research & Development | 0 | 0 | 0 | 40.19K | 558.7K | 3.37M | 4.13M | 5.7M | 5.07M | 5.08M |
R&D % of Revenue | - | - | - | 0.26% | 2.31% | 7.34% | 6.36% | 6.58% | 4.92% | - |
Other Operating Expenses | 125 | -22.08K | 229.95K | 291.37K | 596.98K | 2.66M | 225.13K | 2.98M | 0 | 1M |
Operating Income | 120.44K▲ 0% | -501.86K▼ 516.7% | -2.74M▼ 446.0% | -5.03M▼ 83.7% | -7.38M▼ 46.5% | -12.52M▼ 69.7% | -4.22M▲ 66.3% | -6.72M▼ 59.3% | 9.15M▲ 236.2% | 8.47M▲ 0% |
Operating Margin % | 1.91% | -8.6% | -23.29% | -32.3% | -30.55% | -27.3% | -6.49% | -7.75% | 8.87% | 7.88% |
Operating Income Growth % | 144.26% | -516.68% | -445.98% | -83.74% | -46.51% | -69.7% | 66.33% | -59.32% | 236.19% | - |
EBITDA | 201.09K | -444.92K | -2.62M | -4.74M | -6.6M | -10.15M | -540.13K | -1.79M | 11.81M | 11.45M |
EBITDA Margin % | 3.19% | -7.62% | -22.27% | -30.43% | -27.35% | -22.13% | -0.83% | -2.07% | 11.45% | 10.65% |
EBITDA Growth % | 195.19% | -321.25% | -488.89% | -81.03% | -39.23% | -53.63% | 94.68% | -231.82% | 758.81% | 1860.49% |
D&A (Non-Cash Add-back) | 80.65K | 56.94K | 119.95K | 291.37K | 771.93K | 2.37M | 3.68M | 4.92M | 2.66M | 2.98M |
EBIT | 458.13K | -513.99K | -2.73M | -4.43M | -7.99M | -13.94M | -3.96M | -6.78M | 9.15M | 8.47M |
Net Interest Income | -126.83K | -86.59K | -105.92K | -11.53K | -711 | 0 | -475.78K | -3.11M | -6.76M | -7.23M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 284.75K | 0 | 21.98K | 3.67K | 12.96K |
Interest Expense | 126.83K | 86.59K | 105.92K | 11.53K | 711 | 284.75K | 475.78K | 3.13M | 6.76M | 7.24M |
Other Income/Expense | 210.87K | -98.71K | -95.72K | 589.47K | -617.64K | -1.42M | -224.75K | -3.2M | -9.54M | -10.36M |
Pretax Income | 331.31K▲ 0% | -600.57K▼ 281.3% | -2.84M▼ 372.2% | -4.45M▼ 56.8% | -7.99M▼ 79.8% | -13.94M▼ 74.3% | -4.44M▲ 68.1% | -9.91M▼ 123.2% | -393.12K▲ 96.0% | -1.89M▲ 0% |
Pretax Margin % | 5.25% | -10.29% | -24.1% | -28.52% | -33.11% | -30.4% | -6.83% | -11.44% | -0.38% | -1.76% |
Income Tax | 0 | 0 | 0 | 0 | 0 | -5.84M | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 41.94% | 0% | 0% | 0% | 0% |
Net Income | 331.31K▲ 0% | -600.57K▼ 281.3% | -2.81M▼ 368.6% | -4.36M▼ 54.8% | -7.92M▼ 81.8% | -7.94M▼ 0.2% | -4.3M▲ 45.8% | -9.66M▼ 124.6% | -37.56M▼ 288.7% | -33.58M▲ 0% |
Net Margin % | 5.25% | -10.29% | -23.92% | -27.95% | -32.81% | -17.31% | -6.62% | -11.15% | -36.43% | -31.23% |
Net Income Growth % | 179.69% | -281.27% | -368.57% | -54.81% | -81.84% | -0.2% | 45.79% | -124.59% | -288.66% | -193.85% |
Net Income (Continuing) | 331.31K | -600.57K | -2.84M | -4.45M | -7.99M | -8.09M | -4.44M | -9.91M | -393.12K | -1.89M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -37.17M | -1.44M |
Minority Interest | 0 | 0 | -221.69K | -310.39K | -488.4K | -107.56K | -244.26K | -491.61K | -8.67K | -9.02K |
EPS (Diluted) | 0.09▲ 0% | -0.28▼ 403.7% | -1.37▼ 389.3% | -0.76▲ 44.5% | -1.08▼ 42.1% | -1.00▲ 7.4% | -0.52▲ 48.0% | -1.14▼ 119.2% | -4.36▼ 282.5% | -3.74▲ 0% |
EPS Growth % | 124.26% | -403.69% | -389.29% | 44.53% | -42.11% | 7.41% | 48% | -119.23% | -282.46% | -190.97% |
EPS (Basic) | 0.17 | -0.28 | -1.37 | -0.76 | -1.08 | -1.00 | -0.52 | -1.14 | -4.36 | - |
Diluted Shares Outstanding | 2.09M | 2.17M | 2.13M | 5.73M | 7.34M | 7.91M | 8.28M | 8.48M | 8.62M | 8.99M |
Basic Shares Outstanding | 1.11M | 2.17M | 2.13M | 5.73M | 7.34M | 7.91M | 8.28M | 8.48M | 8.62M | 8.71M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SMTI Balance Sheet
Sanara MedTech Inc. (SMTI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.04M | 978.48K | 8.86M | 4.48M | 24.61M | 20.62M | 19.01M | 33.31M | 33.54M | 31.2M |
Cash & Short-Term Investments | 463.19K | 731.85K | 6.61M | 455.37K | 18.65M | 8.96M | 5.15M | 15.88M | 16.58M | 13.59M |
Cash Only | 463.19K | 731.85K | 6.61M | 455.37K | 18.65M | 8.96M | 5.15M | 15.88M | 16.58M | 13.59M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 836.5K | 164.46K | 1.34M | 2.27M | 2.99M | 7M | 8.53M | 13.55M | 12M | 13.62M |
Days Sales Outstanding | 48.43 | 10.28 | 41.42 | 53.08 | 45.2 | 55.77 | 47.92 | 57.07 | 42.47 | 42.18 |
Inventory | 711.4K | 465.31K | 746.52K | 1.15M | 2.05M | 3.55M | 4.72M | 2.75M | 3.95M | 3.12M |
Days Inventory Outstanding | 322.14 | 334.71 | 225.32 | 259.25 | 323.46 | 203.65 | 219.28 | 123.45 | 141.54 | 134.5 |
Other Current Assets | 0 | -409.58K | 0 | 0 | 0 | 1.1M | 608.41K | 1.12M | 1.02M | 865.32K |
Total Non-Current Assets | 180.5K | 2.06M | 2.26M | 5.34M | 11.79M | 40.42M | 54.87M | 54.79M | 39.4M | 38.08M |
Property, Plant & Equipment | 63.21K | 52.83K | 790.2K | 1.15M | 2.04M | 2.22M | 3.25M | 1.88M | 2.53M | 2.45M |
Fixed Asset Turnover | 99.74x | 110.51x | 14.89x | 13.60x | 11.82x | 20.62x | 19.98x | 46.10x | 40.72x | 24.51x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 3.6M | 3.6M | 3.6M | 3.6M | 3.6M |
Intangible Assets | 117.29K | 52.27K | 1.47M | 3.1M | 4.73M | 31.51M | 44.93M | 41.01M | 18.64M | 17.86M |
Long-Term Investments | 0 | 1.96M | 0 | 1.1M | 5.02M | 3.08M | 3.08M | 8.3M | 14.63M | 51.9M |
Other Non-Current Assets | 0 | 979.98K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 2.22M▲ 0% | 3.04M▲ 37.2% | 11.12M▲ 265.5% | 9.83M▼ 11.6% | 36.4M▲ 270.4% | 61.04M▲ 67.7% | 73.87M▲ 21.0% | 88.09M▲ 19.3% | 72.94M▼ 17.2% | 69.28M▲ 0% |
Asset Turnover | 2.84x | 1.92x | 1.06x | 1.59x | 0.66x | 0.75x | 0.88x | 0.98x | 1.41x | 1.38x |
Asset Growth % | 2.15% | 37.16% | 265.45% | -11.61% | 270.4% | 67.7% | 21.03% | 19.25% | -17.2% | -30.44% |
Total Current Liabilities | 2.12M | 404K | 2.64M | 3.54M | 6.02M | 12.81M | 13.77M | 15.29M | 18.63M | 13.7M |
Accounts Payable | 225.46K | 117.47K | 406.17K | 494.84K | 593.97K | 1.43M | 2M | 1.5M | 2.34M | 921.24K |
Days Payables Outstanding | 102.1 | 84.5 | 122.59 | 111.72 | 93.8 | 81.87 | 93.05 | 67.25 | 83.83 | 56.66 |
Short-Term Debt | 1.2M | 0 | 0 | 0 | 0 | 0 | 580.36K | 0 | 353.23K | 367.94K |
Deferred Revenue (Current) | 13.92K | 0 | 0 | 0 | 0 | 0 | 2.05M | 0 | 1.23M | 1.23M |
Other Current Liabilities | 13.92K | 44.69K | 0 | 0 | 0 | 1.16M | -947.68K | 0 | 235K | 3.33M |
Current Ratio | 0.96x | 2.42x | 3.35x | 1.27x | 4.09x | 1.61x | 1.38x | 2.18x | 1.80x | 2.28x |
Quick Ratio | 0.63x | 1.27x | 3.07x | 0.94x | 3.75x | 1.33x | 1.04x | 2.00x | 1.59x | 2.05x |
Cash Conversion Cycle | 268.47 | 260.5 | 144.15 | 200.61 | 274.86 | 177.55 | 174.15 | 113.26 | 100.18 | 120.02 |
Total Non-Current Liabilities | 1.43M | 1.53M | 2.08M | 446.09K | 222.15K | 6.51M | 15.52M | 33.89M | 48.39M | 48.56M |
Long-Term Debt | 0 | 1.5M | 1.5M | 0 | 0 | 0 | 9.11M | 30.69M | 45.97M | 46.23M |
Capital Lease Obligations | 0 | 0 | 481.38K | 355.8K | 222.15K | 505.29K | 1.74M | 1.24M | 1.87M | 6.65M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 25.98K | 103.56K | 90.29K | 0 | 6M | 4.66M | 1.96M | 548.13K | 559.6K |
Total Liabilities | 2.12M | 1.93M | 4.72M | 3.99M | 6.24M | 19.32M | 29.28M | 49.18M | 67.01M | 62.26M |
Total Debt | 1.2M | 1.5M | 2.1M | 481.38K | 425.44K | 819.22K | 11.79M | 32.29M | 48.19M | 48.37M |
Net Debt | 736.81K | 768.15K | -4.51M | 26.02K | -18.23M | -8.14M | 6.64M | 16.41M | 31.61M | 34.77M |
Debt / Equity | 11.70x | 1.35x | 0.33x | 0.08x | 0.01x | 0.02x | 0.26x | 0.83x | 8.13x | 6.89x |
Debt / EBITDA | 5.97x | - | - | - | - | - | - | - | 4.08x | 4.22x |
Net Debt / EBITDA | 3.66x | - | - | - | - | - | - | - | 2.68x | 3.04x |
Interest Coverage | 3.61x | -5.94x | -25.77x | -384.60x | -11242.03x | -48.95x | -8.33x | -2.17x | 1.35x | 1.17x |
Total Equity | 102.54K▲ 0% | 1.11M▲ 984.5% | 6.39M▲ 474.8% | 5.84M▼ 8.6% | 30.15M▲ 416.3% | 41.72M▲ 38.4% | 44.59M▲ 6.9% | 38.91M▼ 12.7% | 5.93M▼ 84.8% | 7.02M▲ 0% |
Equity Growth % | 124.24% | 984.53% | 474.83% | -8.64% | 416.28% | 38.37% | 6.87% | -12.73% | -84.76% | -264.59% |
Book Value per Share | 0.05 | 0.51 | 3.00 | 1.02 | 4.11 | 5.28 | 5.39 | 4.59 | 0.69 | 0.78 |
Total Shareholders' Equity | 102.54K | 1.11M | 6.61M | 6.15M | 30.64M | 41.83M | 44.83M | 39.4M | 5.93M | 7.03M |
Common Stock | 113.43K | 236.65K | 3.57K | 6.3K | 7.68K | 8.3K | 8.54K | 8.75K | 8.95K | 9.17K |
Retained Earnings | -46.87M | -47.47M | -2.68M | -7.03M | -15.24M | -23.39M | -28.04M | -37.78M | -75.3M | -74.5M |
Treasury Stock | -12.04K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -56.95K | -70.12K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | -221.69K | -310.39K | -488.4K | -107.56K | -244.26K | -491.61K | -8.67K | -9.02K |
SMTI Cash Flow Statement
Sanara MedTech Inc. (SMTI) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -139.86K | 277.14K | -2.17M | -4.03M | -4.81M | -5.55M | -3.25M | -23.78K | 6.79M | 6.32M |
Operating CF Margin % | -2.22% | 4.75% | -18.42% | -25.88% | -19.94% | -12.12% | -4.99% | -0.03% | 6.58% | - |
Operating CF Growth % | -134.18% | 298.15% | -882.05% | -86.15% | -19.33% | -15.38% | 41.57% | 99.27% | 28634.43% | 594.75% |
Net Income | 331.31K | -600.57K | -2.84M | -4.45M | -7.99M | -8.09M | -4.44M | -9.91M | -27.66M | -33.58M |
Depreciation & Amortization | 80.65K | 83.89K | 119.95K | 291.37K | 596.98K | 2.37M | 3.68M | 4.92M | 28.56M | 28.02M |
Stock-Based Compensation | 60.25K | 14.87K | 0 | 1.4M | 2.67M | 2.7M | 3.44M | 4.44M | 718.71K | 442.14K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | -5.84M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -197.62K | 87.71K | 407.33K | -106.08K | 1.1M | 2.79M | -2.64M | 1.44M | 9.02M | 8.5M |
Working Capital Changes | -354.2K | 706.11K | 141.1K | -1.18M | -1.18M | 517.62K | -3.28M | -911.72K | -3.84M | -6.96M |
Change in Receivables | -64.41K | 609.23K | -324.37K | -961.46K | -774.8K | -2.27M | -1.73M | -4.54M | 4.03M | 1.96M |
Change in Inventory | -420.42K | 262.89K | -401.65K | -719.81K | -1.15M | -517.27K | -1.55M | 1.44M | -431.33K | 939.46K |
Change in Payables | -6.71K | -168K | -84.64K | 88.67K | 99.13K | -423.75K | 575.15K | -471.21K | 1.24M | -781.12K |
Cash from Investing | -85.88K | -8.48K | -1.2M | -2.74M | -5.28M | -3.51M | -10.21M | -6.61M | -8.36M | -9.84M |
Capital Expenditures | -85.88K | -8.48K | -182.82K | -544.37K | -171.87K | -147.01K | -265.25K | -205.85K | -4.42M | -2.74M |
CapEx % of Revenue | 1.36% | 0.15% | 1.55% | 3.49% | 0.71% | 0.32% | 0.41% | 0.24% | 4.29% | 2.55% |
Acquisitions | 0 | 0 | 508.97K | 0 | 0 | -2.52M | -9.94M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -41.98K | 0 | -1.52M | -1.1M | -578.59K | -598.45K | 650 | -1.1M | -10.47M | -17.14M |
Cash from Financing | -144.55K | -208.1K | 9.8M | 622.33K | 28.3M | -627.35K | 9.64M | 17.37M | -8.48M | -3.58M |
Debt Issued (Net) | -3.77K | 0 | 0 | 583K | 0 | 0 | 9.69M | 19.59M | 0 | -12.07M |
Equity Issued (Net) | 50.05K | 0 | 0 | 0 | 28.94M | 0 | 911.37K | -75K | 0 | 0 |
Dividends Paid | -32.49K | -223.11K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -190.84K | 208.1K | 9.8M | 39.33K | -642.52K | -627.35K | -958.59K | -2.15M | -8.48M | 8.49M |
Net Change in Cash | -370.29K▲ 0% | 268.66K▲ 172.6% | 6.44M▲ 2295.4% | -6.16M▼ 195.7% | 18.2M▲ 395.6% | -9.69M▼ 153.3% | -3.81M▲ 60.7% | 10.73M▲ 381.5% | -10.03M▼ 193.5% | -7.09M▲ 0% |
Free Cash Flow | -225.74K▲ 0% | 268.66K▲ 219.0% | -3.87M▼ 1541.5% | -5.68M▼ 46.6% | -5.56M▲ 2.0% | -6.3M▼ 13.2% | -3.51M▲ 44.3% | -253.08K▲ 92.8% | 2.16M▲ 953.9% | 3.37M▲ 0% |
FCF Margin % | -3.58% | 4.6% | -32.91% | -36.43% | -23.05% | -13.75% | -5.4% | -0.29% | 2.1% | 3.14% |
FCF Growth % | -155.57% | 219.01% | -1541.49% | -46.64% | 2.01% | -13.24% | 44.29% | 92.79% | 953.86% | 245.75% |
FCF per Share | -0.11 | 0.12 | -1.82 | -0.99 | -0.76 | -0.80 | -0.42 | -0.03 | 0.25 | 0.38 |
FCF Conversion (FCF/Net Income) | -0.42x | -0.46x | 0.77x | 0.93x | 0.61x | 0.70x | 0.75x | 0.00x | -0.18x | -0.10x |
Interest Paid | 0 | 0 | 43.98K | 0 | 711 | 206 | 283.95K | 1.58M | 0 | -626.78K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SMTI Key Ratios
Sanara MedTech Inc. (SMTI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 323.11% | -98.89% | -75% | -71.23% | -44.02% | -22.09% | -9.97% | -23.15% | -167.53% | -246.55% |
Return on Invested Capital (ROIC) | 15.04% | -27.68% | -109.32% | -97.5% | -62.19% | -41.26% | -7.45% | -9.45% | 14.77% | 13.97% |
Gross Margin | 87.22% | 91.31% | 89.72% | 89.63% | 90.43% | 86.12% | 87.92% | 90.61% | 90.13% | 91.19% |
Net Margin | 5.25% | -10.29% | -23.92% | -27.95% | -32.81% | -17.31% | -6.62% | -11.15% | -36.43% | -31.23% |
Debt / Equity | 11.70x | 1.35x | 0.33x | 0.08x | 0.01x | 0.02x | 0.26x | 0.83x | 8.13x | 6.89x |
Interest Coverage | 3.61x | -5.94x | -25.77x | -384.60x | -11242.03x | -48.95x | -8.33x | -2.17x | 1.35x | 1.17x |
FCF Conversion | -0.42x | -0.46x | 0.77x | 0.93x | 0.61x | 0.70x | 0.75x | 0.00x | -0.18x | -0.10x |
Revenue Growth | 14.47% | -7.41% | 101.56% | 32.47% | 54.9% | 89.87% | 41.77% | 33.36% | 18.97% | 17.41% |
Related:SMTI Dividend History·SMTI Revenue History·SMTI Price History·SMTI P/E History·SMTI Financial Ratios·SMTI Institutional Holders
SMTI SEC Filings & Documents
Sanara MedTech Inc. (SMTI) SEC filings — annual & quarterly reports (10-K, 10-Q)
SMTI Frequently Asked Questions
Sanara MedTech Inc. (SMTI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Sanara MedTech Inc. (SMTI) reported $107.5M in revenue for fiscal year 2025. This represents a 4677% increase from $2.3M in 1999.
Sanara MedTech Inc. (SMTI) grew revenue by 19.0% over the past year. This is strong growth.
Sanara MedTech Inc. (SMTI) reported a net loss of $33.6M for fiscal year 2025.
Dividend & Returns
Sanara MedTech Inc. (SMTI) has a return on equity (ROE) of -167.5%. Negative ROE indicates the company is unprofitable.
Sanara MedTech Inc. (SMTI) generated $3.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.